Page last updated: 2024-11-05

6-methyluracil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6-methyluracil: RN given refers to unlabeled cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

6-methyluracil : A pyrimidone that is uracil with a methyl group at position 6. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID12283
CHEMBL ID1650614
CHEBI ID74733
SCHEMBL ID60308
SCHEMBL ID21990343
MeSH IDM0052175

Synonyms (80)

Synonym
HMS1762E01
unii-5o052w0g6i
5o052w0g6i ,
BB 0256780
6mu ,
AB-323/25048156
2,4-dihydroxy-6-methylpyrimidine
metacyl
uracil, 6-methyl-
wln: t6mvmvj f1
626-48-2
4-methyluracil
2,3h)-pyrimidinedione, 6-methyl-
methacyl
2(1h)-pyrimidinone, 4-hydroxy-6-methyl-
nsc9456
nsc-9456
pseudothymine
6-methyluracil
6-methyl-1h-pyrimidine-2,4-dione
inchi=1/c5h6n2o2/c1-3-2-4(8)7-5(9)6-3/h2h,1h3,(h2,6,7,8,9
6-methylpyrimidine-2,4(1h,3h)-dione
2,4(1h,3h)-pyrimidinedione, 6-methyl-
6-methyluracil, 97% (hplc)
einecs 210-949-4
ai3-25472
hsdb 5508
2,4-pyrimidinediol, 6-methyl-
nsc 9456
awd 23-15
6-methyl-2,4(1h,3h)-pyrimidinedione
pseudothymine (van)
AC-2536
bdbm50106396
chebi:74733 ,
chembl1650614 ,
M0454
AKOS000120980
AKOS002303990
A15712
6-methylpyrimidine-2,4-diol
24pyrimidinedione6methyl
STL283926
BP-12331
FT-0610121
SCHEMBL60308
6-methylpyrimidine-2,4-dione
2,4-dihydroxy-6-methyl-pyrimidine
6-methyl-2,4(1h,3h)pyrimidinedione
AM81337
6-methyluracil [hsdb]
methyluracil [who-dd]
methyluracil, 4-
6-methyluracil [mi]
cas-626-48-2
NCGC00357256-01
tox21_304049
dtxsid8052308 ,
dtxcid9030880
Q-200556
4-(6)-methyluracil
6-methyl-2,4(1h,3h)-pyrimidinedione #
STL426163
6-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione
STR00504
1-boc-3-(2-fluoro-benzylamino)-piperidine
mfcd00006028
4-hydroxy-6-methyl-1,2-dihydro-pyrimidin-2-one
4-methyl-2.6-dioxypyrimidin
CS-0017143
Z56871945
Q4161980
F0322-0043
BCP26951
SCHEMBL21990343
EN300-17078
D70607
SB57748
SY001859
HY-Y1125

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" However it acts toxically on tumor cells though it is not toxic for intact cells so that its action is different as compared to that of cytotoxic agents."( [Toxicity of para-aminobenzhydrazide and its influence on nucleic acid biosynthesis in cultures of normal and tumor cells].
Filov, VA; Onishchuk, FD; Tret'iakov, AV, 1989
)
0.28
"The work experimentally confirms the metyluracyl influence on repair shortening of the small intestine tissue damaged by cyclophosphamide toxic effects by morphological and morphometric methods of investigation."( MORPHOLOGICAL FOUNDATION OF METHYLURACYL APPLICATION FOR CORRECTION OF CYCLOPHOSPHAMIDE TOXIC EFFECT ON RATS SMALL INTESTINE TISSUES.
Bondarchuk, AO, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pyrimidoneA pyrimidine carrying one or more oxo substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency15.35530.001530.607315,848.9004AID1224841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 1Homo sapiens (human)Ki57.76000.00001.372610.0000AID1238072
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (1)

Processvia Protein(s)Taxonomy
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1238073Inhibition of human erythrocytes CA2 using 4-nitrophenylacetate as substrate by esterase assay2015Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
Synthesis and carbonic anhydrase inhibitory properties of novel uracil derivatives.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566700Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1238072Inhibition of human erythrocytes CA1 using 4-nitrophenylacetate as substrate by esterase assay2015Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
Synthesis and carbonic anhydrase inhibitory properties of novel uracil derivatives.
AID1238074Competitive inhibition of human erythrocytes CA1 using 4-nitrophenylacetate as substrate by Lineweaver-Burk plot analysis2015Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
Synthesis and carbonic anhydrase inhibitory properties of novel uracil derivatives.
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566707Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (125)

TimeframeStudies, This Drug (%)All Drugs %
pre-199063 (50.40)18.7374
1990's22 (17.60)18.2507
2000's15 (12.00)29.6817
2010's22 (17.60)24.3611
2020's3 (2.40)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.65 (24.57)
Research Supply Index5.10 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index37.30 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (2.52%)5.53%
Reviews2 (1.26%)6.00%
Case Studies5 (3.14%)4.05%
Observational0 (0.00%)0.25%
Other148 (93.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]